Study Evaluating Drug CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (CinCor)

In by ECIR

Study Evaluating Drug CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (CinCor)

  • Hidden
  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

1. Patients must be on a stable regimen of ≥ 3 high blood pressure medications (one of which is a diuretic)
2. Have a seated Blood pressure of ≥ 130/80 mmHg

Exclusion Criteria

1. A seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg
2. BMI > 40 kg/m2
3. Using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache)
4. Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen
5. Is not willing or not able to discontinue taking a potassium supplement
6. eGFR < 45 mL/min/1.73m2 7. NYHA stage III or IV chronic heart failure 8. Stroke, TIA, hypertensive encephalopathy, ACS, or hospitalization for heart failure within 6 months 9. CABG, valve replacement, peripheral arterial bypass surgery, or PCI within 6 months 10. atrial fibrillation 11. HbA1c > 9.5%
12. Potassium < 3.5 mEq/L or > 5.0 mEq/L

Back to Current Studies